Evaluation of Commercially Available Viral Transport Medium (VTM) for SARS-CoV-2 Inactivation and Use in Point-of-Care (POC) Testing
- Supplementary File 1:
ZIP-Document (ZIP, 2098 KiB)
van Bockel, D.; Munier, C.M.L.; Turville, S.; Badman, S.G.; Walker, G.; Stella, A.O.; Aggarwal, A.; Yeang, M.; Condylios, A.; Kelleher, A.D.; Applegate, T.L.; Vallely, A.; Whiley, D.; Rawlinson, W.; Cunningham, P.; Kaldor, J.; Guy, R. Evaluation of Commercially Available Viral Transport Medium (VTM) for SARS-CoV-2 Inactivation and Use in Point-of-Care (POC) Testing. Viruses 2020, 12, 1208. https://doi.org/10.3390/v12111208
van Bockel D, Munier CML, Turville S, Badman SG, Walker G, Stella AO, Aggarwal A, Yeang M, Condylios A, Kelleher AD, Applegate TL, Vallely A, Whiley D, Rawlinson W, Cunningham P, Kaldor J, Guy R. Evaluation of Commercially Available Viral Transport Medium (VTM) for SARS-CoV-2 Inactivation and Use in Point-of-Care (POC) Testing. Viruses. 2020; 12(11):1208. https://doi.org/10.3390/v12111208
Chicago/Turabian Stylevan Bockel, David, C. Mee Ling Munier, Stuart Turville, Steven G. Badman, Gregory Walker, Alberto Ospina Stella, Anupriya Aggarwal, Malinna Yeang, Anna Condylios, Anthony D. Kelleher, Tanya L. Applegate, Andrew Vallely, David Whiley, William Rawlinson, Phillip Cunningham, John Kaldor, and Rebecca Guy. 2020. "Evaluation of Commercially Available Viral Transport Medium (VTM) for SARS-CoV-2 Inactivation and Use in Point-of-Care (POC) Testing" Viruses 12, no. 11: 1208. https://doi.org/10.3390/v12111208